The $750 million deal aims to integrate AI-powered technology and image management systems into pathology laboratory workflows.
Roche has entered into a definitive merger agreement to acquire PathAI, a US-based company specializing in digital pathology and artificial intelligence (AI)-powered technology for pathology laboratories and the biopharma industry.
The acquisition builds on a partnership between the two companies that began in 2021 and was expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to closing conditions, the entity will become part of the Roche Diagnostics division in the second half of 2026.
The move is intended to strengthen Roche’s position in digital pathology by moving manual workflows toward automated, AI-driven processes. Digital pathology creates high-resolution digital images from physical tissue on slides, which allows pathologists to use AI tools to assist diagnostic workflows and provide faster results.
“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better-tailored treatment regimens,” says Matt Sause, CEO of Roche Diagnostics, in a release. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”
PathAI’s AISight image management system software integrates analysis and workflow capabilities within the digital pathology laboratory. Roche intends to scale this solution globally to address the growing pathology market.
The acquisition also enhances Roche’s biopharma services, including clinical trial support and translational research. According to the company, combining these capabilities will support the discovery of new biomarkers, potential drug targets, and diagnostic tools.
“Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed,” says Andy Beck, CEO and co-founder of PathAI, in a release.
Under the terms of the agreement, Roche will pay an upfront purchase price of $750 million. The deal also includes additional milestone payments of up to $300 million. The transaction is subject to customary closing conditions, including antitrust and regulatory approvals.
ID 76159822 © Jetcityimage | Dreamstime.com
